References
- Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B, et al. Leishmaniasis in HIV infection. J Postgrad Med 2003; 49: 39–49
- Campino L, Pratlong F, Abranches P, Rioux JA, Santos-Gomes G, Alves-Pires C, et al. Leishmaniasis in Portugal: enzyme polymorphism of Leishmania infantum based on the identification of 213 strains. Trop Med Int Health 2006; 11: 1708–14
- Desjeux P, Alvar J. Leishmana/HIV coinfections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97(Suppl 1)S3–15
- Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the centre of the Indian epidemic. Clin Infect Dis 2000; 31: 1104–7
- Croft SL, Coombs GH. Leishmaniasis: current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19: 502–8
- Pintado V, López-Velez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect 2001; 7: 291–300
- Burk K, David M, Junge K, Sindermann H. Overview on the clinical development of miltefosine solution (Miltex) for the treatment of cutaneous breast cancer. Drugs Today 1994; 30: 59–72
- Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkylphosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987; 36: 263–6
- Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36: 1630–4
- Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739–46
- Thakur CP, Sinha PK, Singh RK, Hassan SM, Narain S. Miltefosine in a case of visceral leishmaniasis with HIV coinfection, and rising incidence of the disease in India. Trans R Soc Trop Med Hyg 2000; 94: 696–7
- Sindermann H, Engel KR, Fisher C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromized patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39: 1520–3
- Murray HW. Suppression of post-treatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 2000; 44: 3235–6
- Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. Medicine (Baltimore) 2001; 80: 54–73
- Laguna F, Adrados M, Alvar J, et al. Visceral leishmaniasis in patients infected with the human immunodeficiency vírus. Eur J Clin Microbiol Infect Dis 1997; 16: 898–903
- Lafeuillade A, Chaffanjon P, Delbeke E, Quilichini R, et al. Maintenance itraconazole for visceral leishmaniasis in HIV infection. Am J Med 1992; 92: 449
- Ribera E, Ocana I, de Otero J, Cortes E, Gasser I, Pahissa A, et al. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100: 496–501
- Lazanas MC, Tsekes GA, Papandreou S, Harhalakis N, Scandali A, Nikiforakis E, et al. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 1993; 7: 1018–9
- López-Vélez R, Videla S, Marquez M, Boix V, Jiménez-Mejías ME, Górgolas M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53: 540–3
- Pérez-Victoria FJ, Sánchez-Canete MP, Seifert K, Croft SL, Sundar S, Castanys S, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 2006; 9: 26–39
- Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T-cells and activated macrophage microbicidal mechanisms. J Infect Dis 2000; 181: 795–9
- Ritmeijer K, Dejenie A, Asefa Y, Hundie TB, Mesure J, Boots G, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43: 357–64
- Olliaro PL, Ridley RG, Engel J, Sindermann H, Bryceson ADM. Miltefosine in visceral leishmaniasis. Lancet Infect Dis 2003; 3: 70